AMSBIO Announce Modified mRNA for Reprogramming of Stem Cells

AMSBIO has today announced the release of highly modified synthetic 5-prime capped mRNA products for the reprogramming of human pluripotent stem cells. The products are ready-to-use and provide a simple and safe, non-integrating methodology for reprogramming cell fate, based on the administration of synthetic modified mRNA. This method greatly increases efficiency whilst reducing the innate antiviral response of viral protocols.

Clinical applications of induced pluripotent stem cells (iPSCs) have traditionally been limited by the low efficiency of iPSC derivation and the fact that most protocols modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPSCs toward clinically applicable cell types are not possible by viral methods.

AMSBIO have a range of ready-to-use, highly modified mRNAs including Kfl4, c-Myc, Oct4, Sox2, LIN28 mRNA, and eGFP control, in customised formats for your research. These proven synthetic adaptations of 5-prime, 3-prime and internal mRNA structures enable reprogramming of multiple human cell types to pluripotency with conversion efficiencies that greatly surpass established methods. Furthermore this same technology can be used to efficiently direct the differentiation of mRNA-induced pluripotent stem cells into terminally differentiated cells and can be employed as an alternative to DNA-based gene therapy.

This technology represents a safe, non-mutagenic and efficient strategy for somatic cell reprogramming and directing cell fate that has broad applicability for basic research, disease modelling, tissue-engineering and regenerative medicine.